Kim Jae-Hong, Yang Changsop, Yoo Jaehee, Park Gwang-Cheon, Kang Byoung-Kab, Kim Ae-Ran, Kim Jihye, Nam Dongwoo, Hong Yejin
Department of Acupuncture and Moxibustion Medicine, College of Korean Medicine, Dongshin University, Naju, Republic of Korea.
Clinical Research Center, Dongshin University Gwangju Korean Medicine Hospital, Gwangju, Republic of Korea.
Front Med (Lausanne). 2023 Feb 9;10:1021255. doi: 10.3389/fmed.2023.1021255. eCollection 2023.
We aim to obtain clinical trial data regarding the safety, efficacy, and usefulness of invasive laser acupuncture (ILA) for non-specific chronic low back pain (NSCLBP) through a randomized placebo-controlled trial.
Our clinical trial will be an assessor- and patient-blinded, prospective, parallel-arm, multi-center, randomized placebo-controlled clinical trial. One hundred and six participants with NSCLBP will be allocated evenly to the 650 ILA or control group. All participants will receive education on exercise and self-management. The 650 ILA group will undergo 650 nm ILA for 10 min, and the control group will undergo sham ILA for 10 min per visit, twice a week for 4 weeks, at bilateral GB30, BL23, BL24, and BL25. The primary outcome will be the proportion of responders (≥30% reduction in pain visual analogue scale [VAS] without increased use of painkillers) at 3 days after the intervention ends. The secondary outcomes will include changes in the scores of the VAS, European Quality of Life Five Dimension Five Level scale, and Korean version of the Oswestry Disability Index at 3 days after the intervention ends and 8 weeks after the intervention ends.
The results of our study will provide clinical evidence concerning the safety and efficacy of 650 nm ILA for the management of NSCLBP.
https://cris.nih.go.kr/cris/search/detailSearch.do?search_lang=E&focus=reset_12&search_page=M&pageSize=10&page=undefined&seq=21591&status=5&seq_group=21591, identifier KCT0007167.
我们旨在通过一项随机安慰剂对照试验,获取关于侵入性激光针灸(ILA)治疗非特异性慢性下腰痛(NSCLBP)的安全性、有效性和实用性的临床试验数据。
我们的临床试验将是一项评估者和患者双盲、前瞻性、平行组、多中心、随机安慰剂对照临床试验。106名NSCLBP参与者将被平均分配到650 ILA组或对照组。所有参与者都将接受运动和自我管理方面的教育。650 ILA组将接受波长650 nm的ILA治疗10分钟,对照组每次就诊将接受假ILA治疗10分钟,每周两次,共4周,治疗部位为双侧胆经30穴、膀胱经23穴、24穴和25穴。主要结局将是干预结束后3天内有反应者(疼痛视觉模拟量表[VAS]评分降低≥30%且未增加止痛药使用量)的比例。次要结局将包括干预结束后3天和干预结束后8周时VAS评分、欧洲五维健康量表和韩国版Oswestry功能障碍指数的变化。
我们的研究结果将为650 nm ILA治疗NSCLBP的安全性和有效性提供临床证据。